Alpha 2.0
Login Register
» Authors » Adam Currey

Adam Currey

Explore the profile of Adam Currey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 287
Followers 0
Related Specialties
Oncology
Radiology
General Surgery
Top 10 Co-Authors
Carmen Bergom
J Frank Wilson
Tracy Kelly
Candice Johnstone
Amanda L Kong
Howard M Sandler
Elizabeth Gore
Antonetta C Houweling
Xiaojian Chen
Helena M Verkooijen
Published In
Int J Radiat Oncol Biol Phys
Front Oncol
Adv Radiat Oncol
J Clin Oncol
Pract Radiat Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
Ellison C, Martens M, Alvarez Argote J, Benz S, Currey A, Johnstone C, et al.
JTO Clin Res Rep . 2024 Nov; 5(12):100537. PMID: 39555223
Background: The standard of care for unresectable locally advanced NSCLC is concurrent chemotherapy and radiation (CRT) followed by adjuvant durvalumab, established by the PACIFIC trial, which revealed acceptable although higher...
2.
Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
SenthilKumar G, Schottstaedt A, Peterson L, Pedersen L, Chitambar C, Vistocky A, et al.
Cancer Res Commun . 2024 Mar; 4(5):1211-1226. PMID: 38530195
Purpose: Among patients with breast cancer undergoing radiotherapy, posttreatment cardiovascular disease and worsened quality of life (QoL) are leading causes of morbidity and mortality. To overcome these negative radiotherapy effects,...
3.
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, et al.
JAMA Oncol . 2023 Sep; 9(11):1565-1573. PMID: 37768670
Importance: Patients with locally advanced non-human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti-epidermal growth factor receptor (EGFR) antibody improves overall...
4.
Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology
Conger R, Mora J, Straza M, Erickson B, Lawton C, Schultz C, et al.
Adv Radiat Oncol . 2023 May; 8(4):101206. PMID: 37152489
Purpose: The changes in the recommended use of radiation therapy (RT) in the presence of expanding systemic cancer therapies and technological advances are poorly characterized. We sought to understand the...
5.
SUPPORT: SUrvey of Parental Leave POlicies of RadiaTion Oncology Programs and Residency Applicants
Baniel C, Qu V, Beltran Ponce S, Taparra K, Beadle B, Currey A, et al.
Adv Radiat Oncol . 2023 May; 8(4):101207. PMID: 37124316
Purpose: Recruitment to radiation oncology training programs has recently declined, and gender inequities persist in radiation oncology. Policies that promote inclusivity, such as the updated American College of Graduate Medical...
6.
Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial
Krauss D, Karrison T, Martinez A, Morton G, Yan D, Bruner D, et al.
J Clin Oncol . 2023 Apr; 41(17):3203-3216. PMID: 37104748
Purpose: It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT). Methods: The NRG Oncology/Radiation Therapy...
7.
Breast cancer-related lymphedema rates after modern axillary treatments: How accurate are our estimates?
Cortina C, Yen T, Bergom C, Fields B, Craft M, Currey A, et al.
Surgery . 2021 Nov; 171(3):682-686. PMID: 34736790
Background: Clinical trials have demonstrated methods to minimize the risk of breast cancer-related lymphedema while preserving regional control. We sought to determine the percent lifetime-risk of breast cancer-related lymphedema that...
8.
A National Survey of Breast Surgeons and Radiation Oncologists on Contemporary Axillary Management in Mastectomy Patients
Cortina C, Bergom C, Craft M, Fields B, Brazauskas R, Currey A, et al.
Ann Surg Oncol . 2021 Jul; 28(10):5568-5579. PMID: 34247336
Background: Management of axillary lymph nodes in breast cancer has undergone significant change over the past decade through landmark clinical trials. This study aimed to assess national practice patterns in...
9.
Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial
Hall W, Bedi M, Kilari D, Bylow K, Burfeind J, Johnstone C, et al.
Pract Radiat Oncol . 2021 Apr; 11(6):527-533. PMID: 33848618
Purpose: There remains limited data as to the feasibility, safety, and efficacy of higher doses of elective radiation therapy to the pelvic lymph nodes in men with high-risk prostate cancer....
10.
A Pilot Study of Cardiac MRI in Breast Cancer Survivors After Cardiotoxic Chemotherapy and Three-Dimensional Conformal Radiotherapy
Bergom C, Rubenstein J, Wilson J, Welsh A, Ibrahim E, Prior P, et al.
Front Oncol . 2020 Nov; 10:506739. PMID: 33178571
Purpose/objectives: Node-positive breast cancer patients often receive chemotherapy and regional nodal irradiation. The cardiotoxic effects of these treatments, however, may offset some of the survival benefit. Cardiac magnetic resonance (CMR)...